Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Treasury Shares (2022 - 2025)

Amylyx Pharmaceuticals has reported Treasury Shares over the past 4 years, most recently at $2.1 million for Q4 2025.

  • Quarterly results put Treasury Shares at $2.1 million for Q4 2025, down 5.58% from a year ago — trailing twelve months through Dec 2025 was $2.1 million (down 5.58% YoY), and the annual figure for FY2025 was $2.1 million, down 5.58%.
  • Treasury Shares for Q4 2025 was $2.1 million at Amylyx Pharmaceuticals, roughly flat from $2.1 million in the prior quarter.
  • Over the last five years, Treasury Shares for AMLX hit a ceiling of $3.1 million in Q2 2025 and a floor of $596709.0 in Q1 2022.
  • Median Treasury Shares over the past 4 years was $1.2 million (2023), compared with a mean of $1.6 million.
  • Biggest five-year swings in Treasury Shares: surged 174.08% in 2024 and later plummeted 33.58% in 2025.
  • Amylyx Pharmaceuticals' Treasury Shares stood at $740297.0 in 2022, then skyrocketed by 50.28% to $1.1 million in 2023, then soared by 98.91% to $2.2 million in 2024, then fell by 5.58% to $2.1 million in 2025.
  • The last three reported values for Treasury Shares were $2.1 million (Q4 2025), $2.1 million (Q3 2025), and $3.1 million (Q2 2025) per Business Quant data.